Use of endothelium-stabilizing drugs (Capicor) in the comprehensive pathogenetic treatment of patients with Parkinson’s disease (clinical and experimental study)

I.N. Karaban, E.V Rosova, N.V. Karasevych, S.A. Kryzhanovsky, O.A. Gonchar, T.I. Drevitskaya, M.A. Chivlicliy, N.A. Melnik, I.N. Mankovskaya


This investigation is aimed to study and evaluate (a) the effectiveness and tolerance of Capicor capsules, a combination of γ butyrobetaine (60 mg) and meldonium dihydrate (180 mg), manufactured by Olainfarm (Latvia) in the comprehensive treatment of patients with Parkinson’s disease (PD), and (b) to explore the mechanisms of Capicor effect when mo­deling Parkinson-like syndrome. Twenty-two elderly PD patients (disease duration 10.40 ± 4.55 years, stage 2.0–3.0 according to Hoehn-Yahr) were enrolled in our clinical and neurophysio­logic investigation. Experiments were carried out in 20 mature Wistar male rats, being administered rotenone subcutaneously (0.3 mg/100 g body weight) to model parkinsonian syndrome. As a result of Capicor treatment, the oxidative stress (a key me­chanism of disease development) was less significant and the degree of endothelial dysfunction became diminished. Thus, we can recommend Capicor as an endothelium-stabilizing drug in therapy of neurodegenerative processes at all stages of the clinical course of Parkinson’s disease.


Parkinson’s disease; Parkinson-like syndrome; oxidative stress; Capicor


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2020


   Seo анализ сайта